We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-17.8%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.58B
AUM Growth
-$1.09B
Cap. Flow
+$290M
Cap. Flow %
6.34%
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$158M
2
NTRA icon
Natera
NTRA
+$78.7M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$62.7M
4
ANTX icon
AN2 Therapeutics
ANTX
+$55.6M
5
CTKB icon
Cytek Biosciences
CTKB
+$51M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$125M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$61.3M
3
ZGNX
Zogenix, Inc.
ZGNX
+$54.2M
4
CCCC icon
C4 Therapeutics
CCCC
+$44.4M
5
TGTX icon
TG Therapeutics
TGTX
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 98.82%
2 Financials 0.96%
3 Miscellaneous 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVVD icon
101
Invivyd
IVVD
$245M
– –
-4,995,807
Closed -$36.3M
NAUT icon
102
Nautilus Biotechnolgy
NAUT
$113M
– –
-2,436,430
Closed -$12.6M
PHAT icon
103
Phathom Pharmaceuticals
PHAT
$660M
– –
-3,115,008
Closed -$61.3M
SPRY icon
104
ARS Pharmaceuticals
SPRY
$423M
– –
-1,742,186
Closed -$11.6M
TGTX icon
105
TG Therapeutics
TGTX
$8.12B
– –
-2,210,145
Closed -$42M
SYRS
106
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-90,000
Closed -$2.93M
ZGNX
107
DELISTED
Zogenix, Inc.
ZGNX
– –
-3,333,700
Closed -$54.2M
1 2 3 4
5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, RA Capital Management held 107 positions worth $4.58B, down 19% from $5.67B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $290M of net new capital in Q1 2022, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was Biogen: 727,024 shares worth $153M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Novavax, an estimated $125M trimmed.

  • RA Capital Management's largest Q1 2022 buy was Biogen: 727,024 shares worth $153M.
  • RA Capital Management added most to Cytek Biosciences in Q1 2022, an estimated $51M increase.
  • RA Capital Management's biggest Q1 2022 reduction was Novavax, cutting an estimated $125M.
  • RA Capital Management fully exited Phathom Pharmaceuticals in Q1 2022, selling an estimated $61.3M.
  • RA Capital Management's ten largest holdings make up 45% of its $4.58B portfolio in Q1 2022.
  • RA Capital Management opened 10 new positions and closed 11 in Q1 2022.
  • RA Capital Management's portfolio value fell 19% quarter-over-quarter to $4.58B.

Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.